Afatinib Expanded Access Program
This is an open-label, multi-center, single-arm trial, designed to provide early access to afatinib and to provide additional information on the safety and efficacy of afatinib in advanced NSCLC patients who harbor an EGFR mutation.
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||LUX-Lung EAP US; An Open Label Expanded Access Program of Afatinib (BIBW 2992) for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01649284
Show 66 Study Locations
|Study Chair:||Boehringer Ingelheim||Boehringer Ingelheim|